allowing the use of psilocybin in approved clinical settings to treat qualified medical conditions.

HB 1796 creates a regulated program allowing the therapeutic use of psilocybin in clinical settings to treat specific medical conditions, including treatment-resistant depression, PTSD, substance use disorders, and end-of-life care. The bill requires the Department of Health and Human Services to establish a regulatory board and license qualified medical providers, cultivation facilities, and testing laboratories. It sets standards for administration sessions (including preparation, the session itself, and integration) and mandates reporting of adverse events. This program will make psilocybin treatment available to eligible patients under medical supervision in approved settings.